CPI | Jotup

The National Anti-Corruption Commission Thailand joins forces with international agencies to focus on preventing and suppressing transnational corruption

Retrieved on:

Wednesday, April 10, 2024

BANGKOK, THAILAND - Media OutReach Newswire - 25 March 2024 - As emerging with rapid digitalization that paves the way for transnational corruption, the National Anti-Corruption Commission (NACC), Thailand further tightened its collaboration with international organizations in tackling new tactics and complicated illicit activities in accordance with global standards. The NACC's Secretary-General, Mr. Niwatchai Kasemmongkol recently met with representatives of the Nordic Police Liaison Office, led by Mr. Carsten Andersen, Assistant Attache/Liaison Officer, Nordic Police Affairs Department at the Danish Embassy, Thailand and Ms. Jane Ohlsson, Assistant Ambassador/Coordinating Officer for Police Affairs in the Nordic Countries at the Swedish Embassy, Thailand, along with NACC's executives and representatives from the Bureau of International Corruption Affairs and Cases, and the Bureau of Investigation and Special Affairs to enhance cooperation between the NACC enforcement agencies in combating transnational corruption. "Current corruption problems are not limited to any one country. But it has developed into a transnational crime, which affects all countries around the world. Therefore, cooperation between each other in various forms, both bilateral and multilateral is considered an important mechanism for effectively preventing transnational corruption of all kinds," said the NACC secretary-general. He further elaborated that the NACC has collaboration with enforcement agencies from the Nordic countries in both bilateral and multilateral. It has a memorandum of understanding between each other to exchange legal information, coordinate cases, as well as academic cooperation in particular, the sharing of knowledge and anti-corruption practices which is beneficial to raising the level of the Corruption Perceptions Index (CPI) of Thailand. This tie collaboration will help promote the prevention and suppression of corruption in Thailand more effectively. Furthermore, under the cooperation, both sides discussed and exchanged information on international cooperation in criminal matters related to corruption cases between Thailand and the Nordic countries. Denmark has expressed great interest in the NACC's corruption prosecutions and is willing to cooperate in solving transnational corruption cases, while also exchanging information that is beneficial to the fight against corruption. Mr. Niwatchai concluded that the NACC has given great importance to strengthening and expanding the network of cooperation with law enforcement agencies of various countries to deal with transnational corruption continuously. Presently, the NACC, in Thailand has made memoranda of understanding with 25 law enforcement agencies and international organizations, including nine ASEAN countries, the Ministry of Supervision of China, the Independent Authority against Corruption of Mongolia, the Anti-Corruption Commission of Bhutan, the Independent Commission Against Corruption of Australia, the Oversight and Anti-Corruption Authority of Saudi Arabia, the Police Presidium of the Czech Republic, Federal Ministry of the Interior of Austria, Investigative Committee of the Russian Federation, International Department of the National Crime Agency of the United Kingdom, and Office of the Comptroller General of Brazil, as well as World Bank, United Nations Office on Drugs and Crime (UNODC), International Anti-Corruption Academy (IACA), Basel Institute on Governance, United Nations Development Programme (UNDP) and the UN International Organization for Migration (IOM). ----------------------------------------- *This exclusive interview translation is funded by the National Anti-Corruption Fund (NACF). Hashtag: #IntegrityWay #AntiCorruption #ZeroCorruption #NACC #NACF

Key Points:

Therefore, cooperation between each other in various forms, both bilateral and multilateral is considered an important mechanism for effectively preventing transnational corruption of all kinds," said the NACC secretary-general.
He further elaborated that the NACC has collaboration with enforcement agencies from the Nordic countries in both bilateral and multilateral.
Furthermore, under the cooperation, both sides discussed and exchanged information on international cooperation in criminal matters related to corruption cases between Thailand and the Nordic countries.
The National Anti-Corruption Commission (NACC) is a constitutional independent organization and supervised by nine commissioners selected from various professions.

Thor Equities Group Chairman, Joe Sitt, Makes Guest Appearance on Bloomberg Markets to Discuss Inflation, Electric Vehicles, and More

Retrieved on:

Tuesday, April 9, 2024

Aston, Sitt, Government, CPI, Denso, Risk, Gold, Bloomberg Markets, Anxiety, Ferrari, Toyota, Autobahn, Thor, Fear, Cryptocurrency

On Bloomberg Markets, Joe Sitt was asked about the competition among luxury retailers for properties, which he believes “tend to move cyclically with their stock prices and businesses”.

Key Points:

On Bloomberg Markets, Joe Sitt was asked about the competition among luxury retailers for properties, which he believes “tend to move cyclically with their stock prices and businesses”.
Finally, and most remarkably, Joe Sitt discussed electric vehicles, range anxiety, and the Electreon stock which increased 400% since he first mentioned the company on Bloomberg Markets one year prior.
Governments across the world are prioritizing electric roads and the company won government issued tenders for electric roads in France, Sweden, Germany, Israel, Norway and China.
Thor became interested in the company due to the real estate aspect of parking lots and the solution to difficulties of individual recharging.

RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients

Retrieved on:

Tuesday, April 9, 2024

CPI, CPS, Disease, HNSCC, Patient, SAN, Inflammation, Pembrolizumab, HPV, AACR, CCR4, Therapy, PD-L1, Safety, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced safety and efficacy data from its ongoing Phase 2 trial of tivumecirnon in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab in the cohort of patients with advanced head and neck squamous cell carcinoma (HNSCC) whose disease progressed despite previous treatment with CPI therapy (CPI-experienced). The results were presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA.

Key Points:

The results were presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA.
The AACR poster highlighted data from the 32-patient CPI-experienced HNSCC cohort in the trial evaluating tivumecirnon, an oral small molecule CCR4 antagonist designed to block the migration of regulatory T cells, in combination with pembrolizumab.
Patients in this cohort had heavily pretreated disease, with 69% of patients having received three or more (up to six) prior lines of treatment.
In the entire cohort, confirmed responses were observed in 5/32 patients (15.6%) regardless of PD-L1 or HPV status.

BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR

Retrieved on:

Tuesday, April 9, 2024

HER2, ILD, CPI, Survival, Progression-free survival, Central nervous system, Patient, CNS, History, Death, Eribulin, Spacecraft, MD, CBR, TPC, EMBRACE, Life, BCT, AACR, TSX, Therapy, Breast cancer, Safety, Poster, CMO, PFS, ADC, PD-1, Pharmaceutical industry

“ADCs are the latest treatments for very difficult-to-treat advanced metastatic breast cancer.

Key Points:

“ADCs are the latest treatments for very difficult-to-treat advanced metastatic breast cancer.
To our knowledge, there are no effective treatment options in this patient population for whom the progression-free survival prognosis is only a few weeks.
BriaCell will be monitoring ADC resistant patients in its ongoing pivotal Phase 3 study of Bria-IMT™ and CPI in advanced metastatic breast cancer.
Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomized study.

Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on:

Tuesday, April 9, 2024

Immune responses were generated toward the MHC-I negative tumors by combining CTX-009 with CTX-471.

Key Points:

Immune responses were generated toward the MHC-I negative tumors by combining CTX-009 with CTX-471.
The proposed mechanism for this effect suggests the involvement of NK-cells, which can generate potent cell killing independent of MHC-I.
Following mCTX-009 and mCTX-471 combination treatment, superior efficacy was observed in MHC Class I negative tumors.
A copy of the presentation materials can be accessed on the News & Events section under “ Presentations ” of the Company’s website at www.compasstherapeutics.com once the presentation has concluded.

Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial

Retrieved on:

Monday, April 8, 2024

Combination, CPI, Immunosuppression, Patient, Tumor microenvironment, Immunoglobulin G, Merck, Cancer, Pembrolizumab, Lung cancer, AACR, DLT, Clinical trial, Merck & Co., Kineta, NK, VISTA, Pharmaceutical industry

SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today at the American Association for Cancer Research (AACR) in San Diego, CA an update on its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123, an anti-VISTA monoclonal antibody, as monotherapy and in combination with Merck’s anti-PD1 therapy, KEYTRUDA® (pembrolizumab), in patients with advanced solid tumors.

Key Points:

KVA12123 cleared the fifth of six monotherapy dose levels and the second of four cohorts in combination with pembrolizumab.
KVA12123 was well tolerated with no dose limiting toxicities (DLT) or cytokine related adverse events at any dose level.
Patients currently enrolled in the trial will be permitted to continue to participate.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights

Retrieved on:

Monday, April 8, 2024

Research, SOC, Conference, CPI, Ono Pharmaceutical, Patient, Standard of care, Inflammation, Pembrolizumab, IND, Investigational New Drug, WT1, Nivolumab, SITC, FDA, Autoimmunity, Annual general meeting, Pharmaceutical industry

BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, today reported fourth quarter and full year 2023 financial results.

Key Points:

BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, today reported fourth quarter and full year 2023 financial results.
The increase was due to revenue earned from our strategic collaboration agreement entered into with Ono Pharmaceutical in the first quarter of 2023.
As of December 31, 2023, the Company had approximately $48.5 million in cash, cash equivalents and marketable securities compared with $76.3 million as of December 31, 2022.
We expect our current cash, cash equivalents, and marketable securities to fund operations into the first quarter of 2025.

CPI Aerostructures Reports Fourth Quarter and Full Year 2023 Results

Retrieved on:

Saturday, April 6, 2024

EPS, CPI Aerostructures, CPI, Growth

EDGEWOOD, N.Y., April 05, 2024 (GLOBE NEWSWIRE) -- CPI Aerostructures, Inc. (“CPI Aero” or the “Company”) (NYSE American: CVU) today announced financial results for the three and twelve month periods ended December 31, 2023.

Key Points:

Revenue of $86.5 million compared to $83.3 million;
Gross profit of $17.1 million compared to $16.3 million;
Net income of $17.2 million compared to $9.2 million;
Cash flow from operations of $3.9 million compared to $0.9 million;
Debt as of December 31, 2023 of $20.1 million compared to $22.8 million as of December 31, 2022.
EDGEWOOD, N.Y., April 05, 2024 (GLOBE NEWSWIRE) -- CPI Aerostructures, Inc. (“CPI Aero” or the “Company”) (NYSE American: CVU) today announced financial results for the three and twelve month periods ended December 31, 2023.
“We reported solid full-year results, delivering 3.8% increased revenue and a 4.7% increase in gross profit in 2023.
We generated $3.9 million in cash flow from operations during 2023, which allowed us to reduce debt by $2.7 million,” said Dorith Hakim, President and CEO.

Data Center World’s Expo Hall to Feature Hundreds of Innovative Products and Services Data Center Facilities and IT Professionals Need to Know to Plan, Manage and Optimize Data Centers

Retrieved on:

Monday, April 8, 2024

Data Center World , the leading global conference for data center facilities and IT professionals, will feature hundreds of innovative products and services in the Expo Hall.

Key Points:

Data Center World , the leading global conference for data center facilities and IT professionals, will feature hundreds of innovative products and services in the Expo Hall.
The technologies will provide data center facilities and IT professionals with all the information they need to plan, manage and optimize their data centers.
Data Center World is AFCOM’s annual gathering of IT and data center professionals.
Future-proof your data center with hybrid liquid-air cooling, intelligent power handling, and enterprise environment controls by DDC’s DCIM monitoring software.

CPI Card Group® Announces Expansion with New Production Facility in Fort Wayne, Indiana

Retrieved on:

Tuesday, April 9, 2024

Technology, Payments, Finance, Fintech, Banking, Other Technology, Professional Services, Software, Data Management, Certification, Automation, CPI, Software as a service, Digital integration, Sustainability, PMTS, Workforce, LEED, Workplace

This new facility exemplifies CPI's commitment to meeting the evolving needs of its customers and driving innovation in the payments technology industry.

Key Points:

This new facility exemplifies CPI's commitment to meeting the evolving needs of its customers and driving innovation in the payments technology industry.
“CPI is proud to continue operating in the Fort Wayne community, where we are locally engrained with a high-performing team,” said John Lowe, President and Chief Executive Officer.
This is the first time in CPI’s nearly 30-year history that we’ve had the opportunity to build a manufacturing facility to our specifications.
Fort Wayne employees are expected to complete their transition to the new facility by early 2026.